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Introduction
Malignant pleural mesothelioma (MPM) is rare, although its incidence is increasing globally, and is expected to peak in Europe between 2015 and 2020. 1, 2 It is principally caused by occupational exposure to asbestos, but the proportion of patients with nonoccupational exposure has also increased. 2 Despite being banned in Europe, asbestos production and use is still widespread internationally, particularly in Russia, China, Kazakhstan and Brazil. 2, 3 Thus, the incidence of MPM in asbestos-using countries is expected to continue to grow. 1, 2 MPM is often diagnosed at an advanced stage, 4 with an average patient survival time of 6-9 months when left untreated. 5 Combination doublet chemotherapy with cisplatin/pemetrexed is considered to be the front-line standard-of-care treatment for patients with unresectable MPM, 1, 4 yielding a median overall survival (OS) time of approximately 1 year. 6 This is currently the only approved regimen, 4 although carboplatin/pemetrexed is also considered to be a suitable first-line treatment option. 1, 4 With the poor prognosis and the global incidence increasing, there is a clear need for new treatment options.
Several signalling pathways involved in regulating angiogenesis have been implicated in the pathogenesis and prognosis of MPM, including vascular endothelial growth factor (VEGF). 7, 8 The VEGF pathway is a key regulator of angiogenesis and therefore tumour growth, and is an important mitogen for MPM cells. 7 Patients with MPM also often have very high serum concentrations of VEGF, which is considered to be a negative prognostic factor. potential clinical benefit and a manageable safety profile in multiple tumour types. 10 Targeting three major proangiogenic signalling pathways (VEGF, PDGF and FGF) in patients with unresectable MPM may result in greater benefit than other studied antiangiogenic strategies.
Moreover, nintedanib has inhibitory activity against Src. 10 Src plays a role in multiple cancer signalling pathways, is implicated in mesothelioma pathogenesis and inhibition of Src has been proposed as a treatment approach for MPM. 8, 12 In preclinical studies, nintedanib strongly reduced the growth and migratory activity of MPM cell lines and prolonged survival in an orthotopic MPM xenograft model, 13 and it may be viewed as a logical candidate for the treatment of unresectable MPM. LUME-Meso is a randomised, double-blind, placebo-controlled, phase II/III study. The study compares nintedanib in combination with the standard therapy of pemetrexed/cisplatin, followed by maintenance nintedanib, versus placebo in combination with pemetrexed/cisplatin followed by placebo monotherapy for the treatment of patients with unresectable MPM. Originally a double-blind, randomised, phase II exploratory study, the trial was expanded to include a confirmatory phase III part, following recommendations from an 
Patients and Methods
Study Objectives, Design and Dosing Regimen
The overall objective of LUME-Meso is to evaluate the safety and efficacy of standard therapy plus nintedanib followed by continuing nintedanib, versus standard cisplatin/pemetrexed therapy plus placebo followed by continuing placebo, as first-line treatment for patients with unresectable MPM. LUME-Meso is a double-blind, randomised, multicentre, placebo-controlled, phase II/III study. The phase III part broadly follows the phase II design. Enrolled patients are randomised in a 1:1 ratio to receive a maximum of 6 cycles of pemetrexed (500 mg/m 
Eligibility Criteria
The study will be conducted in accordance with the Declaration of Helsinki and necessary ethics committee approval was obtained. All patients provided written informed consent. The phase III part of the study is enrolling patients with histologically confirmed unresectable MPM of the epithelioid subtype. Although patients eligible for radical resection or elective surgery (e.g. pleurectomy) are ineligible, prior surgery ≥4 weeks prior to randomisation is permitted if there has been complete healing and residual measurable disease remains. The main inclusion and exclusion criteria are detailed in Table 1 .
Study Endpoints
The primary endpoint is progression-free survival (PFS), with OS as the key secondary endpoint. Other secondary endpoints are evaluation of objective tumour response and disease control rate, according to modified Response Evaluation Criteria in Solid
Tumors. 15 An additional objective in the phase III part of the study is evaluation of healthrelated quality of life (measured using the EQ-5D health status self-assessment questionnaire 16 and the mesothelioma version of the Lung Cancer Symptom Scale [LCSSMeso]). 17 An exploratory analysis will be conducted by collecting biological samples to investigate the value of potentially predictive or prognostic biomarkers, such as mesothelin, merlin (NF2) and BAP1, via immunohistochemical staining or molecular genetic assays.
Safety will be monitored throughout the study via assessment of changes in laboratory parameters, and the frequency and severity of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
Statistical Design
For analysis of the phase III OS, an adaptive design will be utilised, allowing the required number of events to be reassessed at a pre-planned interim analysis. 18 This enables the uncertainty of the treatment effect to be accounted for, ensuring that the study is sufficiently powered to statistically assess OS. The statistical power of a trial, and thus its success, is dependent on the accuracy of the original clinical estimates. One advantage of an adaptive design is that it ensures, despite uncertainties in these parameters at commencement, that the trial is powered appropriately to achieve its objectives and results in an efficient trial with potentially reduced study duration and demand on resources. 18 For the double-blind, randomised, phase II study, sample size was selected for proofof-clinical-concept and all planned analyses were intended to be descriptive. Following DMC analysis, it was recommended that the study be expanded to include a confirmatory phase III part. Under recommendation from regulatory authorities, the phase II data were unblinded and the primary PFS analysis was undertaken to assist precise planning of the phase III part, including estimation of sample size. Phase II patients will not be included in the confirmatory phase III analyses.
The results obtained at the time of the primary PFS analysis of the phase II part of the study were used to estimate the sample size and statistical assumptions for the phase III part of the study. At the time of the primary PFS analysis, the PFS data were considered to be mature (79% of events available) but the OS data were considered to still be immature with only 53% of events available. Based on this analysis, the phase III part of the study was planned with a sample size of 450 patients. This would provide a power of 90% to detect a statistically significant and clinically meaningful improvement in the primary endpoint, PFS. In planning the statistical analysis of the key secondary endpoint, OS, in the phase III part, a two-stage adaptive design is being implemented. This will account for the greater degree of uncertainty around the estimated OS treatment effect resulting from the still immature OS dataset available at the time of the primary phase II PFS analysis. For the analysis of OS in the phase III part, two potential scenarios will be evaluated at the time of the primary PFS analysis. If at the time of the primary PFS analysis the difference in PFS between study arms is statistically significant, an interim OS analysis will be performed by an external DMC. If the difference in OS between study arms is statistically significant, then the study will be declared positive for the primary and key secondary endpoints and enrolment will be stopped; if the difference is not yet statistically significant, the final number of OS events will be reassessed.
This provision ensures that the trial will provide 80% power to detect a statistically significant and clinically meaningful OS treatment effect at the time of the final OS analysis in the phase III part of the trial.
Conclusion
The LUME-Meso phase II/III trial will determine if the addition of nintedanib to the standard treatment regimen of pemetrexed/cisplatin offers clinical benefit in terms of PFS, the primary endpoint, and OS, the key secondary endpoint. The phase III part of the trial is active, and patients with unresectable MPM that meet the eligibility criteria are currently being enrolled at participating centres across North and South America, Europe, Africa, Australia and Asia. 
